130 related articles for article (PubMed ID: 16525490)
1. Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia.
Heim D; Friess D; Christen S; Stüssi G; Meyer-Monard S; Tichelli A; Passweg JR; Gratwohl A
Leukemia; 2006 May; 20(5):898-900. PubMed ID: 16525490
[No Abstract] [Full Text] [Related]
2. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Deau B; Nicolini FE; Guilhot J; Huguet F; Guerci A; Legros L; Pautas C; Berthou C; Guyotat D; Cony-Makhoul P; Gardembas M; Michallet M; Hayette S; Cayuela JM; Weiss IR; Réa D; Castaigne S; Mahon FX; Guilhot F; Rousselot P
Leuk Res; 2011 Jun; 35(6):777-82. PubMed ID: 21145590
[TBL] [Abstract][Full Text] [Related]
3. Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
Breccia M; Capria S; Iori AP; Foà R; Alimena G; Meloni G
Acta Haematol; 2010; 124(3):150-2. PubMed ID: 20938169
[No Abstract] [Full Text] [Related]
4. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
Koh LP; Hwang WY; Chuah CT; Linn YC; Goh YT; Tan CH; Ng HJ; Tan PH
Bone Marrow Transplant; 2003 Feb; 31(4):305-8. PubMed ID: 12621468
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.
Savani BN; Srinivasan R; Espinoza-Delgado I; Dorrance C; Takahashi Y; Igarashi T; Rezvani K; Lundqvist A; Barrett AJ; Childs RW
Lancet Oncol; 2005 Oct; 6(10):809-12. PubMed ID: 16198987
[No Abstract] [Full Text] [Related]
6. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
[TBL] [Abstract][Full Text] [Related]
7. [Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
Boqué C; Grañena A
Sangre (Barc); 1998 Apr; 43(2):155-63. PubMed ID: 9656777
[No Abstract] [Full Text] [Related]
8. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
9. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
Kim HJ; Jung CW; Kim K; Ahn JS; Kim WS; Park K; Ko YH; Kang WK; Park K
J Clin Oncol; 2006 Aug; 24(24):4028-9. PubMed ID: 16921058
[No Abstract] [Full Text] [Related]
10. Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate.
Zonder JA; Schiffer CA
Curr Hematol Rep; 2003 Jan; 2(1):57-64. PubMed ID: 12901155
[TBL] [Abstract][Full Text] [Related]
11. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.
Fang B; Li N; Song Y; Han Q; Zhao RC
Ann Hematol; 2010 Nov; 89(11):1099-105. PubMed ID: 20499235
[TBL] [Abstract][Full Text] [Related]
12. Autotransplantation for chronic myeloid leukemia: is it useful?
Olavarria E
Haematologica; 2002 Jan; 87(1):3-6. PubMed ID: 11801458
[No Abstract] [Full Text] [Related]
13. [Successful attainment of the third chronic phase by autologous peripheral blood stem cell transplantation and imatinib in a patient with chronic myeloid leukemia].
Tabata S; Ohno T; Tomo K; Hishita T; Hada S; Mizumoto T; Furukawa H
Rinsho Ketsueki; 2003 May; 44(5):313-7. PubMed ID: 12822405
[TBL] [Abstract][Full Text] [Related]
14. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M
Bone Marrow Transplant; 2007 Feb; 39(3):189-91. PubMed ID: 17211436
[No Abstract] [Full Text] [Related]
15. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon.
Hernández-Boluda JC; Carreras E; Cervantes F; Marín P; Arellano-Rodrigo E; Rovira M; Solé F; Lloveras E; Espinet B; Ocejo A; Montserrat E
Haematologica; 2002 Jan; 87(1):17-22. PubMed ID: 11801461
[TBL] [Abstract][Full Text] [Related]
16. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
17. Management decisions in chronic myeloid leukemia.
Goldman JM; Marin D
Semin Hematol; 2003 Jan; 40(1):97-103. PubMed ID: 12563616
[TBL] [Abstract][Full Text] [Related]
18. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
Hui CH; Goh KY; White D; Branford S; Grigg A; Seymour JF; Kwan YL; Walsh S; Hoyt R; Trickett A; Rudzki B; Ma DD; To LB; Hughes TP
Leukemia; 2003 May; 17(5):821-8. PubMed ID: 12750692
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).
Fischer T; Reifenrath C; Hess GR; Corsetti MT; Kreil S; Beck J; Meinhardt P; Beltrami G; Schuch B; Gschaidmeier H; Hehlmann R; Hochhaus A; Carella A; Huber C
Leukemia; 2002 Jul; 16(7):1220-8. PubMed ID: 12094246
[TBL] [Abstract][Full Text] [Related]
20. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]